Your browser doesn't support javascript.
loading
The PanCareFollowUp Care Intervention: A European harmonised approach to person-centred guideline-based survivorship care after childhood, adolescent and young adult cancer.
van Kalsbeek, Rebecca J; Mulder, Renée L; Haupt, Riccardo; Muraca, Monica; Hjorth, Lars; Follin, Cecilia; Kepak, Tomas; Kepakova, Katerina; Uyttebroeck, Anne; Mangelschots, Marlies; Winther, Jeanette Falck; Loonen, Jacqueline J; Michel, Gisela; Bardi, Edit; Elmerdahl Frederiksen, Line; den Hartogh, Jaap; Mader, Luzius; Roser, Katharina; Schneider, Carina; Brown, Morven C; Brunhofer, Melanie; Göttgens, Irene; Hermens, Rosella P M G; Kienesberger, Anita; Korevaar, Joke C; Skinner, Roderick; van der Pal, Helena J H; Kremer, Leontine C M.
Afiliación
  • van Kalsbeek RJ; Princess Máxima Centre for Paediatric Oncology, Utrecht, the Netherlands.
  • Mulder RL; Princess Máxima Centre for Paediatric Oncology, Utrecht, the Netherlands.
  • Haupt R; Epidemiology and Biostatistics Unit and DOPO Clinic, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Muraca M; Epidemiology and Biostatistics Unit and DOPO Clinic, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Hjorth L; Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Paediatrics, Lund, Sweden.
  • Follin C; Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Oncology, Lund, Sweden.
  • Kepak T; International Clinical Research Centre (FNUSA-ICRC), St. Anne's University Hospital, Masaryk University, Brno, Czech Republic.
  • Kepakova K; International Clinical Research Centre (FNUSA-ICRC), St. Anne's University Hospital, Masaryk University, Brno, Czech Republic.
  • Uyttebroeck A; Department of Oncology, Paediatric Oncology, KU Leuven, Department of Paediatric Haematology and Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Mangelschots M; Department of Oncology, Paediatric Oncology, KU Leuven, Department of Paediatric Haematology and Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Winther JF; Childhood Cancer Research Group, Danish Cancer Society Research Centre, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health, Aarhus University Hospital, Aarhus University, Aarhus, Denmark.
  • Loonen JJ; Department of Haematology, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Michel G; Department of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.
  • Bardi E; PanCare, Bussum, the Netherlands; St Anna Children's Hospital, Vienna, Austria; Department of Pediatric and Adolescent Medicine, Kepler University Clinic, Linz, Austria.
  • Elmerdahl Frederiksen L; Childhood Cancer Research Group, Danish Cancer Society Research Centre, Copenhagen, Denmark.
  • den Hartogh J; PanCare, Bussum, the Netherlands; Childhood Cancer International Europe, Vienna, Austria.
  • Mader L; Childhood Cancer Research Group, Danish Cancer Society Research Centre, Copenhagen, Denmark; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
  • Roser K; Department of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.
  • Schneider C; Childhood Cancer International Europe, Vienna, Austria.
  • Brown MC; Population Health Sciences Institute, Newcastle University, Sir James Spence Institute, Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom; Newcastle University Centre for Cancer, Wolfson Childhood Cancer Research Centre, Herschel Building, Newcastle Upon Tyne, United Kingdom.
  • Brunhofer M; Childhood Cancer International Europe, Vienna, Austria.
  • Göttgens I; Department of Primary and Community Care, Radboud University Medical Centre, Radboud Institute for Health Sciences, Nijmegen, the Netherlands.
  • Hermens RPMG; Radboud University Medical Centre, Radboud Institute for Health Sciences, Scientific Institute for Quality of Healthcare (IQ Healthcare), Nijmegen, the Netherlands.
  • Kienesberger A; Childhood Cancer International Europe, Vienna, Austria.
  • Korevaar JC; Netherlands Institute for Health Services Research (Nivel), Utrecht, the Netherlands.
  • Skinner R; Newcastle University Centre for Cancer, Wolfson Childhood Cancer Research Centre, Herschel Building, Newcastle Upon Tyne, United Kingdom; Great North Children's Hospital, Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom; Translational and Clinical Research Institute, Wolfson Childhood C
  • van der Pal HJH; Princess Máxima Centre for Paediatric Oncology, Utrecht, the Netherlands; PanCare, Bussum, the Netherlands. Electronic address: H.J.H.vanderPal@prinsesmaximacentrum.nl.
  • Kremer LCM; Princess Máxima Centre for Paediatric Oncology, Utrecht, the Netherlands; Department of Paediatrics, Emma Children's Hospital, Amsterdam UMC, Amsterdam, the Netherlands; Faculty of Medicine, Utrecht University and Utrecht Medical Centre, Utrecht, the Netherlands.
Eur J Cancer ; 162: 34-44, 2022 02.
Article en En | MEDLINE | ID: mdl-34953441
ABSTRACT

BACKGROUND:

Long-term follow-up (LTFU) care, although endorsed, is not available for the majority of adult survivors of childhood, adolescence and young adult (CAYA) cancer. Barriers to implementation include lack of time, knowledge, personnel and funding. Sustainable solutions are urgently needed to address the needs of CAYA cancer survivors to improve the quality of life and reduce the burden of late effects on survivors, health care systems and society. The European Union-funded PanCareFollowUp project, initiated by the Pan-European Network for Care of Survivors after Childhood and Adolescent Cancer, was established to facilitate the implementation of person-centred survivorship care across Europe. PATIENTS AND

METHODS:

The PanCareFollowUp Care Intervention was co-developed with survivors as part of the PanCareFollowUp project. It is a person-centred approach to survivorship care, supported by guidelines and with flexibility to adapt to local health care settings. The Care Intervention consists of three

steps:

(1) previsit completion of a Survivor Questionnaire (by the survivor) and Treatment Summary (by the health care provider [HCP]), (2) a clinic visit including shared decision-making, and (3) a follow-up call to finalise the individualised Survivorship Care Plan.

RESULTS:

We developed the key components of the PanCareFollowUp Care Intervention a PanCareFollowUp Survivor Questionnaire, Treatment Summary template, Survivorship Care Plan template, and educational materials for HCPs and survivors. Wide implementation of the PanCareFollowUp Care Intervention will be supported with a freely distributed Replication Manual on completion of the PanCareFollowUp project.

CONCLUSIONS:

The PanCareFollowUp Care Intervention will support the implementation of person-centred, guideline-based LTFU care in different health care settings across Europe to improve survivors' health and well-being.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Supervivientes de Cáncer / Neoplasias Tipo de estudio: Guideline / Prognostic_studies / Qualitative_research Aspecto: Patient_preference Límite: Adolescent / Adult / Humans Idioma: En Revista: Eur J Cancer Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Supervivientes de Cáncer / Neoplasias Tipo de estudio: Guideline / Prognostic_studies / Qualitative_research Aspecto: Patient_preference Límite: Adolescent / Adult / Humans Idioma: En Revista: Eur J Cancer Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos
...